Rapid Nexus Nanotech Wound Solutions, Inc.
Rapid Nexus is dedicated to developing innovative wound healing solutions, including the groundbreaking Hemastyl® therapy, aimed at treating non-healing wounds, neuropathy, and preventing amputations. Led by a team of doctors, scientists, and innovators, the company focuses on accelerating tissue regeneration and improving healing outcomes for patients with chronic wounds and diabetic foot ulcers.
Industries
Nr. of Employees
small (1-50)
Rapid Nexus Nanotech Wound Solutions, Inc.
Products
Topical regenerative wound therapeutic (planned market release 2025)
A patented topical regenerative therapeutic formulation combining antimicrobial nanoparticles and matrix scaffold support aimed at peri-wound care and neuropathy-related chronic wounds; reported to promote circulation, tissue growth, and healing in preliminary tests.
Portable peri-wound electrotherapy device
Compact electrotherapy device that administers low-voltage electrical stimulation to wounds to promote angiogenesis, collagen production, and skin cell migration; marketed for both clinic and home use with reported procedure reimbursement pathways.
Topical regenerative wound therapeutic (planned market release 2025)
A patented topical regenerative therapeutic formulation combining antimicrobial nanoparticles and matrix scaffold support aimed at peri-wound care and neuropathy-related chronic wounds; reported to promote circulation, tissue growth, and healing in preliminary tests.
Portable peri-wound electrotherapy device
Compact electrotherapy device that administers low-voltage electrical stimulation to wounds to promote angiogenesis, collagen production, and skin cell migration; marketed for both clinic and home use with reported procedure reimbursement pathways.
Services
Transfer and sharing of developed regenerative wound technology, including prototypes, active substrates, and associated clinical protocols, to external partners.
Provision and coordination of preliminary clinical testing and patient case studies for wound treatments, with documented outcomes and imaging evidence.
Transfer and sharing of developed regenerative wound technology, including prototypes, active substrates, and associated clinical protocols, to external partners.
Provision and coordination of preliminary clinical testing and patient case studies for wound treatments, with documented outcomes and imaging evidence.
Expertise Areas
- Chronic wound healing and diabetic foot ulcer treatment
- Peripheral neuropathy treatment and nerve regeneration
- Regenerative medicine and tissue regeneration
- Medical device development for wound care (portable electrotherapy)
Key Technologies
- Antimicrobial nanoparticles
- Xenograft/matrix scaffold materials
- Electrical stimulation (electrotherapy/EMS) for wound healing
- Angiogenesis stimulation techniques
News & Updates
Patient Case Studies
Repair of multi-year-old non-healing chronic wounds using Hemastyl R® treatment, demonstrating accelerated healing, cell regeneration, and inflammation reduction.
Details on the patented Hemastyl® formula that combines antimicrobial nanoparticles to treat non-healing wounds in diabetic patients.
Patient Case Studies
Repair of multi-year-old non-healing chronic wounds using Hemastyl R® treatment, demonstrating accelerated healing, cell regeneration, and inflammation reduction.
Details on the patented Hemastyl® formula that combines antimicrobial nanoparticles to treat non-healing wounds in diabetic patients.